This program aims to improve HCPs knowledge and competence related to the rationale for and implementation of the use of biologics targeting eosinophil pathways in patients with COPD, as they become available. As a result of this educational activity, learners should be better able to: 1. Identify the rationale for investigating biologics targeting type 2 inflammation for the treatment of patients with chronic obstructive pulmonary disease (COPD) 2. Review the clinical impact of emerging biologics in the treatment of eosinophilic COPD in patients at high risk of exacerbations 3. Outline strategies to implement biologics targeting type 2 eosinophilic inflammation into clinical practice, as they become available
- Provider:Answers in CME Inc. (AiCME)
- Activity Link: https://www.answersincme.com/PES
- Start Date: 2024-09-17 05:00:00
- End Date: 2024-09-17 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: Regeneron Pharmaceuticals, Inc. - Amount: 168852.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest